

Withdrawn: The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs

Mariska van den Berg^{1,2} | Susan Nijboer-Brinksma^{1,2} | Sophie Bos^{1,2} |
Maarten van den Berge^{2,3} | David Lamb⁴ | Martijn van Faassen⁵ | Ido Kema⁵ |
Reinoud Gosens^{1,2} | Loes Kistemaker^{1,2} 

¹Department of Molecular Pharmacology,
University of Groningen, Groningen, The
Netherlands

²Groningen Research Institute for Asthma and
COPD (GRIAC), University of Groningen,
University Medical Center Groningen,
Groningen, The Netherlands

³Department of Pulmonary Diseases,
University of Groningen, University Medical
Center Groningen, Groningen, The
Netherlands

⁴Immunology and Respiratory, Boehringer
Ingelheim Pharma GmbH & Co. KG, Biberach
an der Riss, Germany

⁵Department of Laboratory Medicine,
University Medical Centre Groningen,
University of Groningen, Groningen, The
Netherlands

Correspondence

Loes Kistemaker, Groningen Research Institute
for Asthma and COPD (GRIAC), University of
Groningen, University Medical Center,
Groningen, The Netherlands.
Email: l.e.m.kistemaker@rug.nl

The above article from the *British Journal of Pharmacology*, published online on May 20, 2020 in Wiley Online Library (<http://wileyonlinelibrary.com>) has been withdrawn due to a lack of full disclosure of the chemical structure of the novel TRPA1 antagonist BI01305834, by agreement between the Editor-in-Chief and John Wiley & Sons Inc on behalf of The British Pharmacology Society.